Antitoxin: An antibody produced in response to and capable of neutralizing a specific biologic toxin such as those that cause diphtheria, gas gangrene, or tetanus. Antitoxins are used prophylactically and therapeutically. CONTINUE SCROLLING OR CLICK HERE
The Antivirals and Antitoxins program partners with industry to develop safe and effective therapeutics for disease caused by anthrax, botulinum toxin, smallpox, and filoviruses.
Specific antitoxin neutralizes free toxin only; therefore, if the clinical findings and epidemiology support the diagnosis, antitoxin should be administered promptly, before culture confirmation. Mortality is less than 1% if antitoxin is administered on the first day of disease and increases 20-fold if treatment is delayed until the fourth day.
Antitoxin of human origin might be available in some countries, but in the U. S. only an equine preparation is available. Equine diphtheria antitoxin (DAT) is available only from the CDC through an investigational new drug protocol (CDC Emergency Operations Center; 24-hour telephone: 770-488-7100).
Antitoxin. (Science: protein) a purified antiserum from animals (usually horses) immunised by injections of a toxin or toxoid, administered as a passive immunising agent to neutralise a specific bacterial toxin, for example, botulinus, tetanus or diphtheria.
If the toxin is a venom, the antitoxin formed, or the antiserum containing it, is called an antivenin.
An antitoxin is an antibody with the ability to neutralize a specific toxin. Antitoxins are produced by certain animals, plants, and bacteria in response to toxin exposure. Although they are most effective in neutralizing toxins, they can also kill bacteria and other microorganisms.
The antibodies, which act against toxins (poisonous chemical substances) given out by the germs and neutralise them, are termed as antitoxins.
Your blood is filled with white blood cells. These white blood cells protect your body against pathogens in three ways: They can engulf the 'foreign' cell and digest them. This is called phagocytosis. They can produce antitoxins - antitoxins counteract the toxins that invading bacteria may produce.
Toxoid vaccines (e.g. vaccines for diphtheria and tetanus) are made by purifying the bacterial exotoxin (Flow Chart 26.3). Toxicity of purified exotoxins is then suppressed or inactivated either by heat or with formaldehyde (while maintaining immunogenicity) to form toxoids.
Immunization protects you from disease. Get protected, get immunized. Antitoxins are passive immunization agents. This means they're used to treat some infections, but they don't give long-term protection like vaccines.
Antibodies attack antigens by binding to them. The binding of an antibody to a toxin, for example, can neutralize the poison simply by changing its chemical composition; such antibodies are called antitoxins.
Antitoxin (toxin-neutralizing antibody) is produced from horses by injections of formaldehyde-inactivated DT, like that used in the human vaccine. Antitoxin was first used to treat diphtheria in 1891 and has a clinical efficacy of 97%.
toxoid, bacterial poison (toxin) that is no longer active but retains the property of combining with or stimulating the formation of antibodies. In many bacterial diseases the bacteria itself remains sequestered in one part of the body but produces a poison (exotoxin) that causes the disease manifestations.
(AN-tih-jen) Any substance that causes the body to make an immune response against that substance. Antigens include toxins, chemicals, bacteria, viruses, or other substances that come from outside the body. Body tissues and cells, including cancer cells, also have antigens on them that can cause an immune response.
Toxoids are inactivated bacterial toxins. They retain the ability to stimulate the formation of antitoxins, which are antibodies directed against the bacterial toxin. Adjuvants are inert substances, such as aluminum salts (ie, alum), which enhance vaccine antigenicity by prolonging antigen absorption.
Answer: For medical use in the treatment of human infectious diseases, antitoxins can be produced by injecting an animal with a toxin; most commonl...
Answer: An antibody is defined as a protective protein that is produced by the immune system in response to the presence of a foreign substance, kn...
Answer: Tetanus toxoid can be prepared from the tetanus toxin. This toxin is a substance that tetanus bacteria produce and that attacks nerves and...
Answer: Tetanus is defined as a disease, which is caused by a bacterial infection. Usually, the bacteria are found in the soil, dust, and bowel mov...
Antitoxin for the treatment of tetanus was introduced into medicine by Behring and Kitasato in 1890; large doses (50-100 mL) of serum from horses immunized with tetanus toxin were used. 91 Extensive studies have been done to determine the optimal dose of antitoxin 92 and the possible benefit of intrathecal antitoxin, particularly in tetanus neonatorum, a common problem in developing countries. 93
Antitoxin should be administered as soon as the condition is suspected. Evidence is clear that mortality is higher in children who receive antitoxin late. The antitoxin is made in horses, and a test dose should be given to assess for possible allergy. Diphtheria antitoxin may be difficult to obtain. In the United States, the antitoxin is available only through the Centers for Disease Control and Prevention (CDC). In some other countries, less purified antitoxin is available but cannot be given intravenously. The dose of antitoxin is not related to the patient's size but to the severity of the disease:
The sustainability of higher levels of antitoxin titers after the 12 month booster dose varied with the PBT lot and among individuals. Antitoxin titers persisted a mean of 724 days (range 16 to 2203 days) after a 12-month booster dose, with Lot A2 given from 1991 to 1993, versus only 395 days (range 28 to 1106 days), with PBT Lot PBP-003 given from 1994 to 1996, and 292 days with PBT Lot PBP-004 (range 28 to 1647 days) given from 1997 to 2001 ( P = 0.0161, Sidak; duration of antitoxin titers to Lot A2 greater than Lot PBP-003). 16
Four lots of the PBT were administered to at-risk individuals at USAMRIID between 1979 and 2004: Lot A2 (1979 to 1993), Lot PBP-001 (1991 to 1994), Lot PBP-003 (1994 to 1996), and Lot PBP-004 (1997 to 2004).
Beginning in 1990 , serum was obtained from vaccinated individuals 28 days after dose 3 of the primary series, to confirm the presence of detectable antitoxin before entrance into the laboratory. If no antitoxin antibody was detected (no antitoxin in an undiluted specimen of serum, corresponding to less than 0.02 IU/mL for toxin serotype A), individuals were then given a booster dose of PBT with follow-up serology 28 days post-booster.
Approximately 8% of patients given equine antitoxins develop serum sickness. Up to 10% of individuals have pre-existing hypersensitivity to horse protein. Even very sick patients must be tested before infusion, with desensitization by protocol performed in those showing immediate reactions. 29
The frequency of anaphylaxis and serum sickness is considered to be low in the current era because it is partially influenced by the previous administration of animal serums in the population. However, even patients who are very ill must be tested before infusion of antitoxin, and those who show immediate reactions should undergo a desensitization protocol. 33
Recognizing the continued threat posed by Sudan ebolavirus and Marburg marburgvirus virus and the paucity of products to treat disease caused by these viruses, the Antivirals and Antitoxins program is focusing significant effort on the development of therapeutics against these two threats.
The bacterium Clostridium botulinum can produce neurotoxins that cause botulinum intoxication, a neurological condition that is manifested by ptosis, spreading muscle paralysis, difficulty breathing, and death, if untreated. These toxins are among the most toxic compounds in nature, even at low concentrations. The Centers for Disease Control and Prevention has classified the seven serotypes of botulinum neurotoxins as Category A bioterrorism agents due to their potential for easy preparation and dissemination, high mortality, and the potential for an attack to have a major public health impact.
The Antivirals and Antitoxins program partners with industry to develop safe and effective therapeutics for disease caused by anthrax, botulinum toxin, smallpox, and filoviruses. These high consequence pathogens would cause significant mortality if released into the US population, and the products we develop are designed to mitigate the consequences of deliberate or naturally occurring outbreaks of these biological threats.
In 2009, BARDA partnered with SIGA Technologies to support the advanced development of a smallpox antiviral, TPOXX ®, which was approved on July 13 th, 2018. The approval of TPOXX ® provided the USG with a potent first step in assembling the therapeutic armamentarium against smallpox. Consistent with an Institute of Medicine panel of experts assessment of the development of smallpox antivirals, BARDA pursued development of additional therapeutics with distinct mechanisms of action to obviate the potential for the evolution of viral resistance through selective pressure against TPOXX ® .
CBRN has a proven track record of developing life-saving medical countermeasures. We will continue to work with partners old and new to treat or prevent the medical consequences that result from CBRN threats.
Bacillus anthracis, the etiological agent that causes anthrax, is a serious bioterrorism agent due to the ease of production and delivery of aerosolized spores that result in a high mortality systemic disease. The threat of anthrax is exemplified by the Amerithrax attacks in 2001, where anthrax spores were distributed through the U.S. postal system, causing 22 infections, 11 serious illnesses, and five fatalities despite the treatment of affected individuals with antibiotics.